Monoethanolamine

Monoethanolamine

SCHEMBL170506

CCCCCCCCCCCC(=O)OC(=O)CCC(=O)[O-].NCCO.[Na+]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MPL

The experimentally established mechanism targets of Monoethanolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.44
FABP3 P05413 5/20 0.44
DGKA P23743 1/20 0.43
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
GPR84 Q9NQS5 1/20 0.41
CES2 O00748 3/20 0.41
CES1 P23141 3/20 0.41
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15735322 0.90 CA1 (0.54) CA1FABP3DGKAGPR84CES2
SCHEMBL29078967 0.90 CA1 (0.54) CA1FABP3DGKAGPR84CES2
Potassium Ion SCHEMBL29185344 0.87 FABP3 (0.55) CA1FABP3DGKACES2CES1
Dodecanoic Anhydride SCHEMBL18166491 0.85 CA1 (0.61) CA1FABP3DGKACES2CES1
Propionic Acid SCHEMBL28401062 0.82 DGKA (0.47) CA1FABP3DGKAMAPTCES2
Glycine SCHEMBL29130105 0.82 DGKA (0.47) CA1FABP3DGKAMAPTCES2
Behenic Acid SCHEMBL3344680 0.81 FABP3 (0.61) CA1FABP3CES2CES1
SCHEMBL446588 0.81 FABP3 (0.70) FABP3MAPTLMNA
SCHEMBL2698113 0.81 FABP3 (0.70) FABP3MAPTLMNA
Propionic Acid SCHEMBL28481898 0.80 DGKA (0.52) CA1FABP3DGKACES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120321576-A1 SUNSCREEN COMPOSITION SHISEIDO COMPANY, LTD. (JP) 2012-12-20 US claimed
CN-115105432-B External skin preparation composition 株式会社资生堂 2025-02-11 CN disclosed
CN-118510491-A Expression of silk-stimulated collagen and seal protein-1 and silk-stimulated anti-inflammatory effects 自然进化公司 2024-08-16 CN disclosed
US-20240148622-A1 TOPICAL COMPOSITION FOR SKIN SHISEIDO COMPANY, LTD. (JP) 2024-05-09 US disclosed
US-11964043-B2 Method of emulsification using core-corona type microparticles SHISEIDO COMPANY, LTD. (JP) 2024-04-23 US disclosed
WO-2024059119-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT SOLIOME, INC. (US) 2024-03-21 WO disclosed
WO-2024059862-A2 FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS EVOLVED BY NATURE, INC. (US) 2024-03-21 WO disclosed
US-11931448-B2 Water-in-oil type emulsion composition SHISEIDO COMPANY, LTD. (JP) 2024-03-19 US disclosed
EP-4301790-A1 SUNSCREENS DERIVED FROM KYNURENINES AND OTHER UV-ABSORBING OXIDIZED AMINO ACIDS BOUND TO PEPTIDES OR POLYMERS The Trustees Of Princeton University (US) 2024-01-10 EP disclosed
EP-3520772-B1 COSMETIC RAW MATERIAL USING CORE-CORONA TYPE MICROPARTICLES AND OIL-IN-WATER TYPE EMULSION COSMETIC SHISEIDO CO LTD (JP) 2023-12-20 EP disclosed
US-6602513-B2 Containing dextrin SHISEIDO CO., LTD. (JP) 2003-08-05 US disclosed
US-20030091603-A1 Skin preparations for external use SHISEIDO COMPANY, LTD. (JP) 2003-05-15 US disclosed
EP-0728469-B1 An endermic liniment SHISEIDO CO LTD (JP) 2003-01-15 EP disclosed
US-20020018793-A1 FACE PACK SHISEIDO COMPANY, LTD. (JP) 2002-02-14 US disclosed
EP-1153602-A1 SKIN PREPARATIONS FOR EXTERNAL USE SHISEIDO COMPANY LIMITED (JP) 2001-11-14 EP disclosed
US-6169114-B1 STORAGE STABILITY, THIOL COMPOUND IS ONE OR MORE TYPES OF CYSTEINE AND ITS DERIVATIVES, ZINC OXIDE HAVING A WATER REPELLANT TREATMENT ON ITS SURFACE, SHISEIDO COMPANY, LTD. (JP) 2001-01-02 US disclosed
EP-0976381-A1 DERMATOLOGIC PREPARATION SHISEIDO COMPANY LIMITED (JP) 2000-02-02 EP disclosed
EP-0970681-A1 FACE PACK SHISEIDO COMPANY LIMITED (JP) 2000-01-12 EP disclosed
US-5767158-A FOR BLEACHING SKIN SHISEIDO CO., LTD. (JP) 1998-06-16 US disclosed
EP-0728469-A2 An endermic liniment SHISEIDO COMPANY LIMITED (JP) 1996-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030091603-A1 Skin preparations for external use CUTA, POLR1C, ACMSD CA1 2923/4885FABP3 2827/4885DGKA 2720/4885
US-11964043-B2 Method of emulsification using core-corona type microparticles LIPA, CORO1A, CLTA CA1 1981/4885FABP3 164/4885DGKA 1457/4885
US-11931448-B2 Water-in-oil type emulsion composition FAM83A, LIPA, CUTA CA1 3704/4885FABP3 632/4885DGKA 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.